Answers are grounded in this paper and cite their sources.
Medical literature on Heart Transplantation (HTx) in chagasic cardiomyopathy patients has been plagued by several publications of cases referring to uncommon complications, mainly acute reactivation of the parasitic infection (1–4) and even malignant disease (5). It was considered “contraindicated as an effective treatment of end-stage Chagas’” (2). Although these complications have long been feared (2, 6, 7), many factors argue in favor of this type of treatment of terminal heart failure (HF) in chagasic patients, particularly the young age in which these patients die, the eventual poor response to the treatment of congestive heart failure (CHF) (8, 9), and the availability of drugs that can control or prevent the reactivation of the disease (10, 11). These patients compare favorably with ischemic cardiomyopathy patients with lower incidence of hypertension, dislipidemia, and diabetes mellitus (8, 9), which is an important aspect for the long-term evolution. For us, the use of a tailored protocol with limitation of routine steroids (12), or other form of attenuated immunosuppressive regimen (13) is the clue for the good evolution for chagasic patients after HTx. We favor the abolition of steroids, because there is more sound evidence of reactivation of Chagas’, even in experimental conditions (10, 14, 15), with this drug. Our group published an article in 1996, which showed a lower incidence of rejection after HTx in chagasic patients, compared with controls (12), making the two-drug regimen safer. Fortunately, in a recent review about the topic, a favorable opinion to the indication of heart transplantation in Chagas’s disease is expressed (16). It is now a consensus, established by the First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology, that chagasic patients survive better than other type of cardiomyopathy heart disease. This patient already had the longest survival in that study with 117 chagasic transplanted patients, with 25 patients from our group. These were compared with 407 patients with idiopathic cardiomyopathy and 196 with ischemic cardiomyopathy, the entire Brazilian experience at that time. Survival of ischemic recipients at 1, 4, 8, and 12 years was 59%, 44%, 34%, and 22%, for idiopathic cardiomyopathy it was 69%, 57%, 40%, and 32%, and for chagasic patients it was 71%, 57%, 55%, and 46% (P<0.027). Only two chagasic patients died after reactivation (17, 18). The patient was a 33-year-old male, born in a chagasic endemic area. The serological testes were positive for Chagas’ disease in high titers, and he was in a severe CHF showing little response to the medical therapy. The echocardiogram showed right bundle block with left anterior hemiblock, characteristic of chagasic cardiomyopathy, with an enlargement of cardiac silhouette on x-ray. The echo demonstrated poor contracting left and right ventricles. The pulmonary artery pressure was elevated with values of 14 mm Hg of transpulmonary gradient and 4.2 Wood units of pulmonary vascular resistance. The findings of a larger donor of 27 year-old, 86 kg, against 68 kg of the receptor convinced us, and the patient was operated on June 3, 1985 by Prof. E.J. Zerbini (19). We used preoperative benzonidazol, and the immunosuppressive protocol followed the one used at Harefield, by Prof. M. Yacoub (20), with cyclosporine, azathioprine and no routine steroids. The immediate evolution was complicated by RV dysfunction that improved with pulmonary vasodilators. In the initial series of biopsies, an episode of rejection graded IIIA was detected after 60 days of transplantation and successfully resolved with three daily doses of 1000 mg/d of Solumedrol. The last biopsy, collected after almost 23 years of evolution is shown in Figure 1, with staining in hematoxilin-eosin and Mason tricromic.FIGURE 1.: A recent biopsy shows no signs of rejection and the absence of T. Cruzi (A, B, C). Note mild interstitial fibrosis (D), still a good enough pattern for a 23 year evolution.The long-term evolution of this patient was remarkably uneventful, with strict surveillance of the parasitic reactivation constituted by xenodiagnostic tests in the first year and hemoculture four times a year also always with negative results. The myocardial function, considering the left ventricle (LV) is good, with an enlargement of the right ventricle (RV) with tricuspid incompetence at least moderate. We have progressively reduced the cyclosporine dose that is now of 1.0 mg/kg, and halved the azathioprine dose. In the last 2 years we have introduced enalapril 10 mg/day in two-divided doses, spironolactone 25 mg/day, and hydroclorotiazide 25 mg/day for a mild edema of feet. Clinically the patient is doing well, working full time as a private driver, of an aristocratic lady, exercising regularly, with normal AP. He keeps the same 70 kg from the day of operation. The laboratory data show normal values with creatinine clearance of 70 mL-min. Since 1996 he is using atorvastatine, 10 mg/day at bed time, and amiodarone 100 mg/day was started after atrial fibrillation, restored to sinus rhythm after electrical cardioversion. At the last cardiopulmonary test, the consumption of O2 was 24 mL/kg/min, normal expiratory volumes, no shifts in the ST segment, and normal response of heart rate and AP to the exercise. The last coronary arteriography showed minor irregularities. The published articles on complications, particularly reactivation of Chagas’ disease could raise doubts for the long-term survival of chagasic patients after HTx, which this case helps to clarify. Chagas’ is not different from other asymptomatic chronic infectious disease, like cytomegalovirus and toxoplasmosis, and needs tailored immunosuppression (21, 22). The articles on reactivation should be in our opinion only a necessary warning, but not a deterrent to the useful indication of HTx in young and severely ill chagasic patients. José Henrique Andrade Vila Euryclides Zerbini Delmont Bitencourt Valeria Carvalho Radi Macruz José Pedro Da Silva José Francisco Baumgratz Luciana Da Fonseca Magnus De Souza Carlos D’Andretta Neto Hospital Beneficencia Portuguesa de São Paulo Rua Maestro Cardim São Paulo, Brazil
No takes yet. Share an insight, caveat, or question.
Vila et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: